Haemonetics Corporation (HAE)

Pretax margin

		Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Earnings before tax but after interest (EBT)	US$ in thousands	151,865	141,403	63,629	72,913	87,152
Revenue	US$ in thousands	2,594,610	2,323,320	985,896	860,363	972,079
Pretax margin		5.85%	6.09%	6.45%	8.47%	8.97%

March 31, 2024 calculation

Pretax margin = EBT ÷ Revenue
= $151,865K ÷ $2,594,610K
= 5.85%

Haemonetics Corporation's pretax margin has exhibited a decreasing trend over the past five years, declining from 8.97% in March 2020 to 5.85% in March 2024. This indicates a gradual erosion of the company's ability to generate profits before accounting for income taxes as a percentage of its total revenue. The decreasing pretax margin may suggest that Haemonetics is facing challenges in managing its operating expenses, increasing cost of goods sold, or experiencing pricing pressures in its industry. It would be important for stakeholders to further investigate the factors contributing to this declining profitability trend to assess the company's overall financial health and sustainability.